Current read
Proof of concept from 0 study records, 83 active source records, 43 rapid briefs, and 0 timeline events. Evidence maturity is 0/100, human translation signal is 61/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof.
This lane has plausible intervention signals but is not mature human evidence.
Commercial bias penalty: 100/100. Confidence: 22/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Cell therapies, exosomes, tissue repair, transplantation, and regenerative medicine moving from case reports to trials. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 27/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
CAR-T and cell therapy, stem-cell transplantation, exosome and tissue-repair programs.
What would move this row up?
Current bottleneck
evidence maturity, human translation
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Evidence that would change the map
- Raise evidence maturity from 0/100 with better controlled studies or stronger replication.
- Raise human translation from 27/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not equate patient stories with broad regeneration proof.
- Do not imply commercial stem-cell or exosome clinics are validated by early research.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
Some Early CAR-T Lymphoma Patients Are 10 Years Out Without Relapse
Penn Medicine reports decade-long follow-up from one of the earliest CAR-T lymphoma trials, with some patients alive without relapse after a single infusion.
Why now
Long-term follow-up turns early CAR-T enthusiasm into a decade-scale remission signal for some patients.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
First Child Received Experimental Gene Therapy for Cockayne Syndrome
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
Teen Became First Pediatric Patient Saved by Deceased-Donor Stem Cells
Riley Children's says 14-year-old Noah Britt became the first pediatric patient in the world successfully treated with a bone marrow transplant using stem cells from a deceased donor.
Why now
A local patient story with world-first pediatric framing gives transplant infrastructure a vivid human face.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
World-First HIV-to-HIV Lung Transplant Expanded Donor Access
NYU Langone says Bertrand Nelson received the world's first HIV-positive donor to HIV-positive recipient lung transplant under a research protocol, plus a liver transplant, and is off oxygen after four years.
Why now
A world-first transplant milestone connects patient survival, HIV stigma, organ access, and changing federal transplant policy.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
NHS Pilot Turned a Declined Donor Liver Into a Transplant
Royal Free London says the first NHS Assessment and Recovery Centre transplant used machine perfusion and extra testing to reassess a donor liver that had been declined by all UK units.
Why now
A hospital-pilot milestone creates a concrete organ-access story with strong emotional reach: a previously declined organ became a transplant opportunity.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Expanded CRISPR Therapy to Children as Young as 2
Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.
Why now
The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
GLP-1s, Dopamine, and Addiction: The Substance Use Signal
GLP-1 medications may do more than reduce appetite for food. Early clinical trials, real-world data, and preclinical research suggest they may also affect craving, reward, alcohol intake, and substance-use patterns - but the science is still developing.
VV Signal Score
57
Early or context-dependent
- Sources
- 19
- Studies
- 8
- Claims
- 3